Maintaining Hold on Enhabit, Inc.: Weighing Operational Gains Against Rate Headwinds and Strategic Risks
TD Cowen Sticks to Their Hold Rating for Enhabit, Inc (EHAB)
Enhabit Analyst Ratings
B of A Securities Maintains Underperform on Enhabit, Lowers Price Target to $8
Leerink Partners: Upgraded the Enhabit (EHAB.US) rating from lower than the market to a consistent market rating, with a target price of $8.50.
Enhabit Analyst Ratings
Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target Is $8.50
Hold Rating on Enhabit, Inc. Maintained Amid EBITDA Beat and Ongoing Uncertainties
UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating
Leerink Partners Sticks to Its Sell Rating for Enhabit, Inc (EHAB)
Enhabit Analyst Ratings
Enhabit, Inc (EHAB) Receives a Rating Update From a Top Analyst
Jefferies Downgrades Enhabit to Hold From Buy, Price Target at $8.75
Enhabit, Inc.: A Sell Rating Amid Overly Optimistic Growth Expectations and Financial Challenges
Enhabit Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Enhabit, Inc (EHAB)
UBS Adjusts Enhabit Price Target to $10 From $9.50, Maintains Neutral Rating
Enhabit, Inc (EHAB) Receives a Rating Update From a Top Analyst
Analysts Have Conflicting Sentiments on These Healthcare Companies: Enhabit, Inc (EHAB) and UnitedHealth (UNH)
Enhabit Analyst Ratings